Cardiovascular mortality in hypertensive patients newly prescribed perindopril vs. lisinopril: A 5-year cohort study of 15,622 Chinese subjects

Tsoi, Kelvin K.F.; Wong, Martin C. S.; Tam, Wilson W.S.; Hirai, Hoyee W.; Lao, Xiang Qian; Wang, Haoxiang; Kwan, Mei Po; Cheung, Clement S; Tong, Ellen L.H.; Cheung, Ngai Tseung; Yan, Bryan P.; Meng, Huadong; Griffiths, Siân

doi:10.1016/j.ijcard.2014.07.114

Cited by 11 publications

(8 citation statements)

References 50 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[34] They also showed that elderly patients who had heart failure had higher mortality rate 30 days after hospital discharge among those prescribed captopril or enalapril compared with Ramipril. [35] Together with our previous studies which showed that hypertensive patients who received lisinopril were more likely than perindopril users to die from cardiovascular disorders or be admitted due to renal disease or diabetes, [13,36] the conclusion of this study was compatible with those from existing literature. The difference in their effectiveness to reduce respiratory disease and all-cause admissions might be due to their different pharmacokinetic and pharmacodynamics activities.…”

Section: Relationship With Literature and Explanation Of Findingssupporting

confidence: 88%

“…[14] We declared that this database has also been employed for analysis in previous studies. [13,[15][16][17][18][19][20][21][22] The present study was performed in accordance with the ethical guidelines of the Declaration of Helsinki. The study was approved by the Clinical Ethics…”

Section: Data Sourcementioning

confidence: 99%

“…[12] Furthermore, in our recent analysis of a populationbased study from 15,622 hypertensive patients, perindopril users were found to have lower all-cause and cardiovascular mortality than lisinopril users. [13] The objective of this study was to compare the effectiveness of perindopril and lisinopril, which were the two most commonly prescribed ACEIs, on reducing hospital admission due to any cause, cardiovascular disease and respiratory disease. We tested the a priori hypothesis that there was no difference in the incidence of admission between the two drug classes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The incidence of all-cause, cardiovascular and respiratory disease admission among 20,252 users of lisinopril vs. perindopril: A cohort study

Wong

Chan

Wang

et al. 2016

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Relationship With Literature and Explanation Of Findingssupporting

confidence: 88%

Section: Data Sourcementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The incidence of all-cause, cardiovascular and respiratory disease admission among 20,252 users of lisinopril vs. perindopril: A cohort study

Wong

Chan

Wang

et al. 2016

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

“… 42 Pharmacogenetical differences may also lead to heterogeneous responses to antihypertensive agents within the same class. 43 With these considerations in mind, further research is required to confirm the effectiveness and magnitude of mortality benefit of cardiovascular risk reduction therapy in South Asians.…”

Section: Discussionmentioning

confidence: 99%

Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada

Morgan

Smolina

et al. 2017

BMJ Open

View full text Add to dashboard Cite

ObjectivesGuidelines recommend ACE inhibitors (ACEi), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs) and diuretics in all patients with diabetes mellitus. However, the effectiveness of these agents in South Asian and Chinese populations is unknown. We sought to determine whether ACEi, ARB, CCB and diuretics are associated with reduced mortality in South Asian, Chinese and other patients with diabetes.DesignPopulation-based cohort study using administrative health databases.SettingProvince of British Columbia, Canada (2006–2013).ParticipantsPatients aged ≥35 years with incident diabetes.Primary and secondary outcome measuresPrimary outcome was all-cause mortality for each medication class compared with untreated patients within each ethnicity. Treatment effect was assessed using inverse probability of treatment weighted Cox proportional hazards models. Medication adherence effect on mortality was also evaluated.Results208 870 patients (13 755 South Asian, 22 871 Chinese, 172 244 other Canadian) were included. ACEi reduced mortality in other patients (HR=0.88, 0.84–0.91), but power was insufficient to evaluate for benefit in Chinese and South Asian patients. ARB and diuretics reduced mortality in Chinese (ARB HR=0.64, 0.50–0.82; diuretics HR=0.77, 0.62–0.96) and other patients (ARB HR=0.69, 0.64–0.74; diuretics HR=0.66, 0.63–0.69) compared with untreated patients. No mortality benefit was observed among South Asians for any drug class or for CCB among all ethnicities. Higher medication adherence was associated with lower mortality for other patients only (HR=0.79, 0.72–0.86).ConclusionsEffectiveness of cardiovascular risk reduction therapy on mortality varies considerably by ethnicity. Further study is needed to evaluate the mortality benefit of antihypertensive agents in South Asians. Inclusion of these ethnic groups in future clinical trials is essential to examine for differential responses.

show abstract

“…However, the different chemical structure and pharmacological features of the various ACE‐inhibitors may account for possible differences in their clinical efficacy. This has been recently supported by a direct comparison between perindopril and lisinopril in a huge cohort of patients with hypertension . In this regard, among the various ACE‐inhibitors, zofenopril due to its cardioprotective properties may have some advantages, which makes it a suitable treatment for diabetic patients with AMI complicated by CHF .…”

Section: Introductionmentioning

confidence: 92%

Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE‐4 Randomized, Double‐Blind Study in Diabetic Patients

Borghi

Omboni

Novo

et al. 2016

Cardiovascular Therapeutics

View full text Add to dashboard Cite

SUMMARYObjective: In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods: The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results: A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as diabetics. The adjusted rate of MACE was lower under zofenopril than under ramipril in both nondiabetics [27.9% vs. 34.9% ramipril; odds ratio, OR and 95% confidence interval: 0.55 (0.35, 0.86)] and diabetics [30.9% vs. 41.3%; 0.56 (0.18, 1.73)], although the difference was statistically significant only for the nondiabetic group (P = 0.013). Zofenopril was superior to ramipril as regards to the primary study endpoint in the subgroup of 157 patients with uncontrolled blood glucose (≥126 mg/dL), regardless of a previous diagnosis of diabetes [0.31 (0.10, 0.90), P = 0.030]. Zofenopril significantly reduced the risk of hospitalization for cardiovascular causes in both nondiabetics [0.64 (0.43, 0.96), P = 0.030] and diabetics [0.38 (0.15, 0.95), P = 0.038], whereas it was not better than ramipril in terms of prevention of cardiovascular deaths. Conclusions: This retrospective analysis of the SMILE-4 study confirmed the good efficacy of zofenopril plus ASA in the prevention of long-term MACE also in the subgroup of patients with diabetes mellitus.

show abstract

Cardiovascular mortality in hypertensive patients newly prescribed perindopril vs. lisinopril: A 5-year cohort study of 15,622 Chinese subjects

Cited by 11 publications

References 50 publications

The incidence of all-cause, cardiovascular and respiratory disease admission among 20,252 users of lisinopril vs. perindopril: A cohort study

The incidence of all-cause, cardiovascular and respiratory disease admission among 20,252 users of lisinopril vs. perindopril: A cohort study

Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada

Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE‐4 Randomized, Double‐Blind Study in Diabetic Patients

Contact Info

Product

Resources

About